Is China Trying To (Slowly) Burst Another Stock Market Bubble?
The pressure point in Asian stock markets this week has been the decline in Chinese equities (the biggest weekly drop in 4 months). Despite a stellar performance of the economy, the outlook for the Shanghai Composite Index isn’t promising as the government is taking advantage of better growth to spur deleveraging. For a market […]
C’est L’Economie Stupide
DOW – 30 = 20,547 SPX – 7 = 2348 NAS – 6 = 5910 RUT – 4 = 1379 10 Y – .01 = 2.24% OIL – 1.17 = 49.54 GOLD + 2.20 = 1284.90 For the week, the Dow Industrials were down 3 days and up 2, but the two gainers were big. […]
Markets Coil Tighter
The market is coiling tighter as investors wait for news and earnings. I don’t know if there really is a short-term trend at the moment, but the VIX is elevated so I think that tips towards a short-term downtrend… not that it really matters much. This chart looks like a cup and handle […]
CAC 40 To Move On Presidential Election Results; FTSE 100 At Support, S&P 500 In Limbo
S&P 500 still wavering in its search for direction; correction over or to continue? FTSE 100 takes a hard hit on election announcement, starting week at key support The big headline for the CAC 40 is the French presidential election on Sunday S&P 500 Markets will start out the week with the French presidential election […]
Can Railroads Prosper Under The Trump Administration?
It is a fact that declining coal shipments have hurt railroad stocks in the past few years. Given that coal is a key revenue-generating commodity for railroad operators, headwinds related to the commodity had affected sector participants big time. However, things are looking up for this key sector. Let’s find out why. Trump Victory a […]
Not Yet Time To ‘Gamble’ On Ocwen Despite Sharp Decline, Says Oppenheimer
Oppenheimer analyst Ben Chittenden, in a note to investors entitled “If You Want to Gamble, Go to Foxwoods,” said it is “very hard” to fully know the outcome of the cease and desist orders and CFPB lawsuit against Ocwen but they, at the least, push out any potential turn in profitability. While he isn’t ready […]
Samsung Bioepis’ Knockoff Latest Competition For Johnson & Johnson’s Blockbuster, Remicade
Johnson & Johnson (JNJ)’s Remicade earned close to $7 billion last year, making it by far the biggest drug in their portfolio, but the FDA has approved a new knockoff…which may finally start to shift the market dynamics toward greater competition with lower prices. Written by John Carroll (ENDpts.com) The FDA approval was unusual among the […]
TIPping Points?
The Federal Reserve’s complete change last year wasn’t something that happened all at once. There were several hints that a lot was going on behind the scenes that may never become public, including five years (now four) down the road when the full policy transcripts are released to the public. There was more interest in […]
